Journal article
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
Journal of clinical lipidology, Vol.5(6), pp.474-482
2011
DOI: 10.1016/j.jacl.2011.06.004
PMID: 22108151
Abstract
Metabolic syndrome (MetS) and atherosclerotic vascular disease (AVD) are associated with increased coronary heart disease risk.
To assess percent change from baseline in lipids and high-sensitivity C-reactive protein (hs-CRP) levels and the proportion of subjects reaching specified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C) and apolipoprotein B (Apo B) single, dual, and triple targets and hs-CRP <2 mg/L among subjects with and without AVD treated with ezetimibe/simvastatin or atorvastatin for 6 weeks.
Adults (N = 1143) with MetS and hypercholesterolemia were randomized to starting and next higher doses of ezetimibe/simvastatin (10/20 or 10/40 mg) or atorvastatin (10, 20, or 40 mg).
Ezetimibe/simvastatin produced significantly greater reductions in evaluated lipids than atorvastatin for most prespecified dose comparisons. More subjects without AVD achieved LDL-C levels <100 mg/dL, non-HDL-C levels <130 mg/dL, and dual LDL-C/non-HDL targets (83%–92% vs 62%–76%) and Apo B <90 mg/dL or triple targets (65%–75% vs 41%–49%) with 40 mg of atorvastatin or 10/20–40 mg of ezetimibe/simvastatin compared with 10 or 20 mg of atorvastatin, respectively. More subjects with AVD achieved LDL-C<70 mg/dL and non-HDL-C<100 mg/dL single and dual targets (65%–80%) and Apo B <80 mg/dL (53%–63%) with 10/20–40 mg of ezetimibe/simvastatin than with 40 mg of atorvastatin (40%–49%). More subjects achieved triple lipid targets with 10/20–40 mg of ezetimibe/simvastatin versus 10–40 mg of atorvastatin (50%–63% vs 24%–40%). Achievement of hs-CRP <2 mg/L was similar across all doses regardless of AVD status.
More intensive therapy was required for >80% of subjects to achieve LDL-C <100 mg/dL and non-HDL-C <130 mg/dL and for the majority of subjects to achieve lower levels of LDL-C <70 mg/dL, non-HDL-C <100 mg/dL, and/or Apo B <90 mg/dL. The effect of ezetimibe on cardiovascular risk reduction has yet to be established. (
Clintrials.gov no:
NCT00409773)
Details
- Title: Subtitle
- Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
- Creators
- Jennifer G Robinson - Departments of Epidemiology & Medicine, University of Iowa College of Public Health, 200 Hawkins Drive SE 223 GH, Iowa City, IA 52242, USAChristie M Ballantyne - Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX, USAWilla Hsueh - Diabetes Research Center, The Methodist Hospital Research Institute, Houston, TX, USAJeffrey Rosen - Clinical Research of South Florida, Coral Gables, FL, USAJianxin Lin - Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, USAArvind Shah - Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, USARobert S Lowe - Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, USAMary E Hanson - Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, USAAndrew M Tershakovec - Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, USA
- Resource Type
- Journal article
- Publication Details
- Journal of clinical lipidology, Vol.5(6), pp.474-482
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.jacl.2011.06.004
- PMID
- 22108151
- ISSN
- 1933-2874
- eISSN
- 1876-4789
- Language
- English
- Date published
- 2011
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995121902771
Metrics
38 Record Views